Eli Lilly: Is Another Monster Quarter Coming

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Confe…

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...

Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating

Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...
TipRanks on MSN

Genmab announces new data from Phase 1/2 RAINFOL-01 trial

Genmab (GMAB) announced updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan, an investigational folate ...
Yahoo

Alpha Kappa Alpha Donates $1.9M To Howard While Unveiling On-Campus Monument

Alpha Kappa Alpha Sorority, Inc. marked a significant milestone last Wednesday as it unveiled a monument on Howard University’s campus alongside a $1.9 million donation. Members gathered for the event ...
Morningstar

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...
The New England Journal of Medicine

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in ...